Close menu




June 2nd, 2020 | 05:58 CEST

Memphasys, Moderna, Paion - Investments in solutions with potential

  • Healthcare
Photo credits: pixabay.com

Biotech companies around the world employ scientists and physicians to study the causes of diseases. The research and development of medical products and solutions usually involves a large number of tests and takes a correspondingly long time. The longer and more extensive this process is, the more capital these companies require from investors. In the race to bring to market preparations or products that improve people's well-being or fulfill desires, the providers of solutions usually have great sales potential and investors may be bought out through a takeover.

time to read: 1 minutes | Author: Mario Hose
ISIN: AU000000MEM5 , US60770K1079 , DE000A0B65S3

Table of contents:


    Biological separation

    Memphasys from Australia has developed a solution for parents with a desire to have children, which allows high-quality sperm to be biologically separated from the man's seminal fluid. The product from Memphasys is called FELIX and increases the chances of success of artificial insemination. The company thus serves a growth market, as more and more couples are deciding to start their professional career first when planning their lives. With increasing age, however, the chance of success of a natural pregnancy decreases and the advice of experts is sought.

    In the second half of 2020, FELIX is to be launched in various countries around the globe. The biological separation process not only works with humans, but can also be used with mammals in the future - also a huge market, according to Alison Coutts Memphasys' market capitalization is currently AUD 52 million at AUD 0.07 per share. The shares are also traded in Germany.

    Covid-19 vaccine hope

    The US biotech company Moderna is in the public eye as it is working on a vaccine against Covid-19, and since the outbreak of the Corona Pandemic, the value of its shares has already risen by around 200%, and at USD 62 per share, its market value is over USD 23 billion. In a recent announcement, the company provided information on the development status. The mid-stage clinical trials have started with 600 patients. Moderna has been researching a vaccine candidate since March 2020 and people are hopeful that a vaccine will provide a way out of the Corona Crisis.

    Approval for anaesthetics

    The Paion shares are also hot at the moment. The company may receive approval for the anesthetic Remimazolam from the US Food and Drug Administration (FDA) in the coming months. "In 2020, Paion's focus will be on evaluating the European Phase III study in general anaesthesia, the regulatory approval process in the US, Europe and other regions, the development of the supply chain and commercial manufacturing of Remimazolam, as well as the market preparation and launch of Remimazolam in different territories," the company announced. Paion's most recent liquidity was approximately EUR 18 million and its share price of EUR 2.29 represents a market value of EUR 143 million.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 23rd, 2022 | 11:28 CEST

    Defence Therapeutics, Amazon, BioNTech - Innovative technologies for health

    • Biotechnology
    • Investments
    • Healthcare

    While WHO Director-General Tedros Adhanom Ghebreyesus sees the end of the Corona pandemic within reach, companies like BioNTech have more products in the pipeline to bring successful drugs to market. In order to ensure that this happens thoroughly and more quickly, Canadian company Defence Therapeutics is stepping up to shorten development cycles with a unique platform technology in oncology. Cancer has still not been eradicated. An end, however, is in sight for Amazon's in-house healthcare division. Amazon Care is closing its doors at the end of the year, but the Seattle-based corporation still cannot let go of the lucrative healthcare business...

    Read

    Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST

    BioNTech, NervGen, Sanofi - The rebound is on the way

    • Biotechnology
    • Healthcare

    Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.

    Read

    Commented by Nico Popp on October 15th, 2021 | 10:10 CEST

    MorphoSys, Sativa Wellness Group, CureVac: Healthcare investments of tomorrow

    • Healthcare

    The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.

    Read